221 related articles for article (PubMed ID: 31101754)
1. Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.
Natoni A; Farrell ML; Harris S; Falank C; Kirkham-McCarthy L; Macauley MS; Reagan MR; O'Dwyer M
Haematologica; 2020; 105(2):457-467. PubMed ID: 31101754
[TBL] [Abstract][Full Text] [Related]
2. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
3. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.
Glavey SV; Manier S; Natoni A; Sacco A; Moschetta M; Reagan MR; Murillo LS; Sahin I; Wu P; Mishima Y; Zhang Y; Zhang W; Zhang Y; Morgan G; Joshi L; Roccaro AM; Ghobrial IM; O'Dwyer ME
Blood; 2014 Sep; 124(11):1765-76. PubMed ID: 25061176
[TBL] [Abstract][Full Text] [Related]
4. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
5. E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.
Natoni A; Smith TAG; Keane N; McEllistrim C; Connolly C; Jha A; Andrulis M; Ellert E; Raab MS; Glavey SV; Kirkham-McCarthy L; Kumar SK; Locatelli-Hoops SC; Oliva I; Fogler WE; Magnani JL; O'Dwyer ME
Leukemia; 2017 Dec; 31(12):2642-2651. PubMed ID: 28439107
[TBL] [Abstract][Full Text] [Related]
6. Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment.
Natoni A; Bohara R; Pandit A; O'Dwyer M
Front Bioeng Biotechnol; 2019; 7():252. PubMed ID: 31637237
[TBL] [Abstract][Full Text] [Related]
7. Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation.
Katayama Y; Hidalgo A; Peired A; Frenette PS
Blood; 2004 Oct; 104(7):2020-6. PubMed ID: 15161666
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
[TBL] [Abstract][Full Text] [Related]
9. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
10. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
[TBL] [Abstract][Full Text] [Related]
12. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.
Martínez-Moreno M; Leiva M; Aguilera-Montilla N; Sevilla-Movilla S; Isern de Val S; Arellano-Sánchez N; Gutiérrez NC; Maldonado R; Martínez-López J; Buño I; García-Marco JA; Sánchez-Mateos P; Hidalgo A; García-Pardo A; Teixidó J
Leukemia; 2016 Apr; 30(4):861-72. PubMed ID: 26658839
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
Abdi J; Mutis T; Garssen J; Redegeld FA
PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
[TBL] [Abstract][Full Text] [Related]
14. Simultaneously Targeting Two Coupled Signalling Molecules in the Mesenchymal Stem Cell Support Efficiently Sensitises the Multiple Myeloma Cell Line H929 to Bortezomib.
Rojas-Zambrano PM; Meyer-Herrera JE; Ruiz-Aparicio PF; Vernot JP
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175864
[TBL] [Abstract][Full Text] [Related]
15. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
16. Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and alpha4beta7.
Masellis-Smith A; Belch AR; Mant MJ; Pilarski LM
Cancer Res; 1997 Mar; 57(5):930-6. PubMed ID: 9041197
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of alpha2,6 sialylation during myeloid maturation: a potential role in myeloid cell release from the bone marrow.
Le Marer N; Skacel PO
J Cell Physiol; 1999 Jun; 179(3):315-24. PubMed ID: 10228950
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.
Colombo M; Garavelli S; Mazzola M; Platonova N; Giannandrea D; Colella R; Apicella L; Lancellotti M; Lesma E; Ancona S; Palano MT; Barbieri M; Taiana E; Lazzari E; Basile A; Turrini M; Pistocchi A; Neri A; Chiaramonte R
Haematologica; 2020 Jul; 105(7):1925-1936. PubMed ID: 31582544
[TBL] [Abstract][Full Text] [Related]
20. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
